Ortivus (ORTI) Q4 2024 earnings summary

Executive summary

• Extensive organizational changes and new business system implemented to support growth and improve financial control.

• Focus on digitalization of pre-hospital care, with MobiMed 5 integration marking a key milestone.

• Market potential for electronic patient records (ePR) estimated at €2 billion annually, with >15% growth rate.

Financial highlights

• Q4 net sales up 10% year-over-year to SEK 21.3 million; full-year net sales down 5% to SEK 80.4 million.

• Q4 gross margin fell to 21% (28% prior year); adjusted gross margin rose to 47% (28%).

• Full-year gross margin at 35% (37%); adjusted gross margin at 42% (37%).

• Q4 EBITDA at SEK -4.4 million; adjusted EBITDA at SEK 2.3 million. Full-year EBITDA at SEK -13.8 million; adjusted EBITDA at SEK -4.9 million.

• Q4 profit after tax at SEK -9.6 million; full-year profit after tax at SEK -24.9 million.

• Cash and cash equivalents at year-end SEK 7.3 million, up from SEK 1.3 million.

Outlook and guidance

• No forecasts provided; forward-looking statements subject to risks and uncertainties.

• Company aims for controlled, profitable growth and further expansion in the UK and Europe.